SEC Form 4 · accession 0001209191-17-048255
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP, CFO & COO
Period of report
Aug 7, 2017
Accepted (ET)
Aug 9, 2017 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2017 | M | 4,250 | $77.31 | A | 120,138 | D | |
| Common StockF2,F3 | Aug 7, 2017 | S | 400 | $154.09 | D | 119,738 | D | |
| Common StockF2,F4 | Aug 7, 2017 | S | 2,600 | $155.29 | D | 117,138 | D | |
| Common StockF2,F5 | Aug 7, 2017 | S | 1,250 | $156.02 | D | 115,888 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $77.31 | Aug 7, 2017 | M | 4,250 | D | — | Feb 4, 2024 | Common Stock | 4,250 | 8,500 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- F2Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $154.09 (range $153.67 to $154.50).
- F4Open market sales reported on this line occurred at a weighted average price of $155.29 (range $154.82 to $155.80).
- F5Open market sales reported on this line occurred at a weighted average price of $156.02 (range $155.87 to $156.26).
- F6The option vests in 16 quarterly installments from 2/5/2014.